Zhejiang Taitan (003036.SZ) received a warning letter from the Zhejiang Securities Regulatory Bureau for violating relevant regulations.
Zhejiang Taitan Co., Ltd. (003036.SZ) announced that the company recently received the "Decision on Taking Measures of Issuing Warning Letters against Zhejiang Taitan Co., Ltd. and Relevant Personnel" issued by the Zhejiang Regulatory Bureau of the China Securities Regulatory Commission. During an on-site inspection, the Zhejiang Regulatory Bureau found the following problems in the company's management and use of raised funds: First, the replacement of raised funds failed to perform the review procedures and disclose information as required; second, some raised funds were used for purposes not in accordance with regulations and such use was not disclosed.
Zhejiang Taitan (003036.SZ) announced that the company recently received the "Decision on Taking Measures of Issuing Warning Letters against Zhejiang Taitan Co., Ltd. and Relevant Personnel" issued by the Zhejiang Regulatory Bureau of the China Securities Regulatory Commission. During an on-site inspection, the Zhejiang Securities Regulatory Bureau found the following problems in the company's management and use of raised funds: First, the replacement of raised funds failed to perform the review procedures and disclose information as required; second, part of the raised funds was used for purposes not in accordance with the prescribed use and was not disclosed.
The company's above-mentioned conduct violated Article 3, Paragraph 1 of the "Administrative Measures for Information Disclosure by Listed Companies" (CSRC Order No. 182), Article 3, Paragraph 1 of the "Administrative Measures for Information Disclosure by Listed Companies" (CSRC Order No. 226), Article 11 of the "Regulatory Guidelines for Listed Companies No. 2 - Regulatory Requirements for the Management and Use of Raised Funds by Listed Companies" (CSRC Announcement [2022] No. 15), and Article 8, Paragraphs 1 and 2 of the "Regulatory Rules for Raised Funds of Listed Companies" (CSRC Announcement [2025] No. 10). The company's Chairman and General Manager Chen Yourong, Chief Financial Officer Pan Mengping, and Board Secretary Pan Xiaoxiao violated Article 4 and Article 51, Paragraph 1 of the "Administrative Measures for Information Disclosure by Listed Companies" (CSRC Order No. 182), and Article 4 and Article 52, Paragraph 1 of the "Administrative Measures for Information Disclosure by Listed Companies" (CSRC Order No. 226), and are responsible for the above-mentioned violations.
In accordance with Article 52 of the "Administrative Measures for Information Disclosure by Listed Companies" (CSRC Order No. 182) and Article 53 of the "Administrative Measures for Information Disclosure by Listed Companies" (CSRC Order No. 226), the Zhejiang Securities Regulatory Bureau decided to take the supervisory and management measure of issuing warning letters separately to the company, Chen Yourong, Pan Mengping, and Pan Xiaoxiao, and to record them in the securities and futures market integrity archive.
Related Articles

Dizal Pharmaceutical (688192.SH): Multiple research results on hematology oncology products selected for the 68th American Society of Hematology (ASH) Annual Meeting

National Grid (NGG.US) raises full-year profit guidance, capital investment soars to 6.7 billion, 70 billion upgrade plan enters acceleration phase

Qinheng Micro's ChiNext IPO application has been accepted. Its main business is the R&D, design, and sales of interface chips and interconnect MCU chips.
Dizal Pharmaceutical (688192.SH): Multiple research results on hematology oncology products selected for the 68th American Society of Hematology (ASH) Annual Meeting

National Grid (NGG.US) raises full-year profit guidance, capital investment soars to 6.7 billion, 70 billion upgrade plan enters acceleration phase

Qinheng Micro's ChiNext IPO application has been accepted. Its main business is the R&D, design, and sales of interface chips and interconnect MCU chips.






